Knowing Regs Key as China Gets Tougher on GMP Inspections
This article was originally published in PharmAsia News
China FDA has significantly beefed up inspections of foreign drug manufacturing sites, underscoring the agency’s increasing assertiveness in regulatory enforcement. Staying out of trouble requires staying on top of local regulatory updates, regulatory experts say.
You may also be interested in...
SHANGHAI - China is expected to be the world's largest vaccine market by 2020, and every vaccine maker is trying to increase their presence to gain market share. However, the new Chinese Pharmacopoeia might put these efforts to an end and almost all vaccines from multinational companies may have to withdraw from China if they fail to comply with new standards
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.